RuiVision Secures Tens of Millions in New Funding Round to Advance AI-Powered Myopia Control Technology

Recently,MetaVision Announces Completion of Tens of Millions of Yuan in New Round of FinancingInvested by Chengdu Huaxi Jinzhi Specialized and New Equity Investment Partnership (referred to as the "Specialized and New Fund") managed by Huaxi Jinzhi, with existing shareholder Innovation Works continuing to increase investment, and WinX Capital serving as the exclusive financial advisor.

This isAnother round of financing within two months after the completion of the A2 round in June 2025, cumulatively receiving continuous support from multiple institutions. The funds from this round will be used to advance the registration of Class III medical devices, the construction of sales systems, brand promotion, as well as the ongoing research and development and upgrading of core products.

# About MetaVision

MetaVision explores a "light-eye-brain" intelligent treatment closed-loop that integrates optical stimulation, neural regulation, and AI feedback, with myopia intervention as the entry point.

• Hardware End: Introduce a bionic optical module for precise output of visual stimuli;

• Algorithm End: Based on AI recognition and personalized output mechanisms, adaptable to different vision conditions, usage habits, and durations.
  This technical pathway has been validated in multi-center clinical studies. Research data from multiple institutions, including Beijing Tongren Hospital, Sichuan West China Hospital, and Wenzhou Medical University Eye Optometry Hospital, showed that in a real-world study of nearly 200 cases over six months, the mean axial elongation in the experimental group was 0.038mm, significantly lower than 0.125mm in the control group, with some subjects showing improvements in refractive status.

In product applicationsMetaVision emphasizes the integration with daily life, proposing a "learn while treating, play while adjusting" seamless intervention model. The company, relying on a network covering hundreds of professional institutions and over 1000 stores, has initially formed an integrated "product-data-service" system, accumulating operational foundations for a long-term prescription-based myopia prevention and control model.

In addition to technology and products, MetaVision also participates in the construction of industry standard systems.At the 2025 International Forum on Innovative Development of Visual Health (VisionChina2025), MetaVision, in collaboration with the Eye Hospital of Wenzhou Medical University, released two group standards: "Technical Specifications for Far-Field Electronic Display Terminals" and "Visual Health Technical Requirements for Display Products—Far-Field Electronic Display Terminals," promoting the standardized implementation of related technologies.

# Conclusion

Investors believe that the optometry market is a mature and large-scale one, with technological iteration expected to give rise to a new batch of industry-leading enterprises. MetaVision’s technical approach features differentiation and has already accumulated multi-center clinical data support, forming initial barriers in user systems and channel networks. Its dual-driven business model of "innovative products + service model" is gradually gaining market validation.

Against the backdrop of myopia prevention and control being incorporated into China's national strategy, the technical approach combining AI with visual neural regulation is attracting increasing attention. As related products enter the registration and large-scale application phase, clinical efficacy validation, long-term compliance, and accessibility will become key benchmarks for future competition in this field.